Easun Capital Markets is a non-banking financial company that primarily invests in stocks, mutual funds, and debt instruments while providing short-term loans to group entities and other businesses.
The company lacks a competitive advantage, evidenced by extremely low average ROCE and ROE that fail to meet the cost of capital. High net margins are a function of low operating costs in a small-scale investment vehicle rather than pricing power or structural barriers to entry.
Management prioritizes reinvestment into low-yielding financial instruments and related-party debt. There is no track record of returning capital to shareholders via dividends, and the returns on retained earnings are consistently poor.
Five years later, the capital has evaporated as the company's role as a low-yield investment vehicle for insiders finally hit a wall. The disconnect between rising revenue and shrinking earnings per share eventually led to a liquidity trap where capital was tied up in non-performing advances against property and related-party loans. Without an audit trail at the database level, financial transparency remained a black box until a major write-down of unquoted equity instruments—previously held at optimistic fair values—forced a massive correction in book value, leaving minority shareholders with a shell of a business that never earned its cost of capital.
RichFakir rates Easun Capital Markets Ltd's business quality as poor — 25/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Easun Capital Markets Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Easun Capital Markets Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Easun Capital Markets Ltd's fair value is about ₹7 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →